Cargando…

Ganoderma: A Cancer Immunotherapy Review

Ganoderma is a significant source of natural fungal medicines and has been used for the treatment of various diseases for many years. However, the use of Ganoderma in cancer immunotherapy is poorly elucidated. In this study, we have analyzed 2,398 English-language papers and 6,968 Chinese-language p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yu, Xu, Xiaowei, Liu, Shujing, Huang, Linfang, Gu, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209820/
https://www.ncbi.nlm.nih.gov/pubmed/30410443
http://dx.doi.org/10.3389/fphar.2018.01217
_version_ 1783366977095467008
author Cao, Yu
Xu, Xiaowei
Liu, Shujing
Huang, Linfang
Gu, Jian
author_facet Cao, Yu
Xu, Xiaowei
Liu, Shujing
Huang, Linfang
Gu, Jian
author_sort Cao, Yu
collection PubMed
description Ganoderma is a significant source of natural fungal medicines and has been used for the treatment of various diseases for many years. However, the use of Ganoderma in cancer immunotherapy is poorly elucidated. In this study, we have analyzed 2,398 English-language papers and 6,968 Chinese-language papers published between 1987 and 2017 by using bibliometrics. A steady growth in the number of publications was observed before 2004, followed by an exponential increase between 2004 and 2017. The most common category for publications about Ganoderma was “Pharmacology & Pharmacy,” in which immunomodulation (25.60%) and cancer treatment (21.40%) were the most popular subcategories. Moreover, we have provided an overview of the bioactive components and combinatorial immunomodulatory effects for the use of Ganoderma in the treatment of cancer, including the major pathways of immune cells. Immunomodulatory protein and polysaccharides are the key bioactive factors responsible for cancer immunotherapy, and the NF-κB and MAPK pathways are the most comprehensively investigated major pathways. Our results indicate that Ganoderma has a broad-spectrum application for the treatment of cancer through the regulation of the immune system. This review provides guidance for future research into the role of Ganoderma in cancer immunotherapy.
format Online
Article
Text
id pubmed-6209820
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62098202018-11-08 Ganoderma: A Cancer Immunotherapy Review Cao, Yu Xu, Xiaowei Liu, Shujing Huang, Linfang Gu, Jian Front Pharmacol Pharmacology Ganoderma is a significant source of natural fungal medicines and has been used for the treatment of various diseases for many years. However, the use of Ganoderma in cancer immunotherapy is poorly elucidated. In this study, we have analyzed 2,398 English-language papers and 6,968 Chinese-language papers published between 1987 and 2017 by using bibliometrics. A steady growth in the number of publications was observed before 2004, followed by an exponential increase between 2004 and 2017. The most common category for publications about Ganoderma was “Pharmacology & Pharmacy,” in which immunomodulation (25.60%) and cancer treatment (21.40%) were the most popular subcategories. Moreover, we have provided an overview of the bioactive components and combinatorial immunomodulatory effects for the use of Ganoderma in the treatment of cancer, including the major pathways of immune cells. Immunomodulatory protein and polysaccharides are the key bioactive factors responsible for cancer immunotherapy, and the NF-κB and MAPK pathways are the most comprehensively investigated major pathways. Our results indicate that Ganoderma has a broad-spectrum application for the treatment of cancer through the regulation of the immune system. This review provides guidance for future research into the role of Ganoderma in cancer immunotherapy. Frontiers Media S.A. 2018-10-25 /pmc/articles/PMC6209820/ /pubmed/30410443 http://dx.doi.org/10.3389/fphar.2018.01217 Text en Copyright © 2018 Cao, Xu, Liu, Huang and Gu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Cao, Yu
Xu, Xiaowei
Liu, Shujing
Huang, Linfang
Gu, Jian
Ganoderma: A Cancer Immunotherapy Review
title Ganoderma: A Cancer Immunotherapy Review
title_full Ganoderma: A Cancer Immunotherapy Review
title_fullStr Ganoderma: A Cancer Immunotherapy Review
title_full_unstemmed Ganoderma: A Cancer Immunotherapy Review
title_short Ganoderma: A Cancer Immunotherapy Review
title_sort ganoderma: a cancer immunotherapy review
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209820/
https://www.ncbi.nlm.nih.gov/pubmed/30410443
http://dx.doi.org/10.3389/fphar.2018.01217
work_keys_str_mv AT caoyu ganodermaacancerimmunotherapyreview
AT xuxiaowei ganodermaacancerimmunotherapyreview
AT liushujing ganodermaacancerimmunotherapyreview
AT huanglinfang ganodermaacancerimmunotherapyreview
AT gujian ganodermaacancerimmunotherapyreview